Citation Impact
Citing Papers
International consensus diagnostic criteria for neuromyelitis optica spectrum disorders
2015 Standout
Interleukin-1 in the pathogenesis and treatment of inflammatory diseases
2011 Standout
Severe interstitial lung disease in connective tissue disease: rituximab as rescue therapy
2012
Open label trial of anakinra in active ankylosing spondylitis over 24 weeks
2004
Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor α inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial
2009
Active immunization with IL‐1 displayed on virus‐like particles protects from autoimmune arthritis
2008
Considerations with the use of biological therapy in the treatment of rheumatoid arthritis
2004
Efficacy of low-dose rituximab for mixed cryoglobulinemia
2007
The Rheumatoid Arthritis Drug Development Model: a case study in Bayesian clinical trial simulation
2009
Current evidence for the management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of RA
2010
NF-κB signaling in inflammation
2017 Standout
Consensus statement on the use of rituximab in patients with rheumatoid arthritis
2006
Cholinergic agonists inhibit HMGB1 release and improve survival in experimental sepsis
2004 Standout
New therapies for treatment of rheumatoid arthritis
2007
The addition of tocilizumab to DMARD therapy for rheumatoid arthritis: a meta-analysis of randomized controlled trials
2009
Rheumatoid arthritis
2016 Standout
Essential role of microRNA‐155 in the pathogenesis of autoimmune arthritis in mice
2011
Inhibition of joint damage and improved clinical outcomes with rituximab plus methotrexate in early active rheumatoid arthritis: the IMAGE trial
2010
Interleukin-10-Producing Plasmablasts Exert Regulatory Function in Autoimmune Inflammation
2014 StandoutNobel
Pro-resolving lipid mediators are leads for resolution physiology
2014 StandoutNature
The NLRP3 inflammasome: molecular activation and regulation to therapeutics
2019 Standout
Should Rituximab be Considered as the First-Choice Treatment for Severe Autoimmune Rheumatic Diseases?
2007
Risk of cardiovascular events and rofecoxib: cumulative meta-analysis
2004
SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials
2013 Standout
Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation
2015 Standout
Cardiovascular Events Associated with Rofecoxib in a Colorectal Adenoma Chemoprevention Trial
2005 Standout
Safety of biological therapies following rituximab treatment in rheumatoid arthritis patients
2009
Physiology and immunology of the cholinergic antiinflammatory pathway
2007 Standout
Updated consensus statement on biological agents, specifically tumour necrosis factor α (TNFα) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2005
2005
A multicenter phase I/II trial of rituximab for refractory systemic lupus erythematosus
2007
Therapies for Active Rheumatoid Arthritis after Methotrexate Failure
2013
Systemic sclerosis
2017 Standout
The Risk of Infections with Biologic Therapies for Rheumatoid Arthritis
2009
Risk of serious infections during rituximab, abatacept and anakinra treatments for rheumatoid arthritis: meta-analyses of randomised placebo-controlled trials
2008
Psoriasis
2021 Standout
B-cell depletion with rituximab in the treatment of autoimmune diseases
2007
The Pathogenesis of Rheumatoid Arthritis
2011 Standout
Efficacy of Anti‐CD20 Treatment in Patients with Rheumatoid Arthritis Resistant to a Combination of Methotrexate/Anti‐TNF Therapy
2007
Anti‐CD20 therapy in patients with rheumatoid arthritis: Predictors of response and B cell subset regeneration after repeated treatment
2008
The role of DMARDs in reducing the immunogenicity of TNF inhibitors in chronic inflammatory diseases
2013
Synovial tissue response to rituximab: mechanism of action and identification of biomarkers of response
2007
Rituximab for rheumatoid arthritis refractory to anti–tumor necrosis factor therapy: Results of a multicenter, randomized, double‐blind, placebo‐controlled, phase III trial evaluating primary efficacy and safety at twenty‐four weeks
2006
B-cell inhibitors as therapy for rheumatoid arthritis: An update
2007
A multicentre, double blind, randomised, placebo controlled trial of anakinra (Kineret), a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis treated with background methotrexate
2004
Cardiovascular Risk Associated with Celecoxib in a Clinical Trial for Colorectal Adenoma Prevention
2005 Standout
B-Cell Depletion with Rituximab in Relapsing–Remitting Multiple Sclerosis
2008 Standout
How antirheumatic drugs protect joints from damage in rheumatoid arthritis
2008
Delivery technologies for cancer immunotherapy
2019 Standout
Forget personalised medicine and focus on abating disease activity
2012
Therapeutic antibodies for autoimmunity and inflammation
2010
Therapeutic strategies to reduce IL-1 activity in treating local and systemic inflammation
2004
Antibody therapy of cancer
2012 Standout
Bone as a Target Organ in Rheumatic Disease: Impact on Osteoclasts and Osteoblasts
2015
Inflammation and Colon Cancer
2010 Standout
Psoriasis
2015 Standout
Graphical Tools for Network Meta-Analysis in STATA
2013 Standout
Treatment of neuromyelitis optica: Review and recommendations
2012
Rheumatoid arthritis therapy reappraisal: strategies, opportunities and challenges
2015
Graves' Ophthalmopathy
2010 Standout
Immunopathology of multiple sclerosis
2015 Standout
Ankylosing spondylitis
2007 Standout
Improvement of Sjögren's syndrome after two infusions of rituximab (anti‐CD20)
2007
Longterm Safety of Patients Receiving Rituximab in Rheumatoid Arthritis Clinical Trials
2010
Systemic Lupus Erythematosus
2011 Standout
Anakinra for Rheumatoid Arthritis: A Systematic Review
2009
Adjunctive anakinra in patients with active rheumatoid arthritis despite methotrexate, or leflunomide, or cyclosporin-A monotherapy: a 48-week, comparative, prospective study
2008
How were new medicines discovered?
2011 Standout
A multicenter survey of rituximab therapy for refractory antineutrophil cytoplasmic antibody–associated vasculitis
2009
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2010
2011 Standout
Type 1 diabetes
2013 Standout
Designing hydrogels for controlled drug delivery
2016 Standout
Anakinra: an inhibitor of IL-1 for the treatment of rheumatoid arthritis
2004
Non-steroidal anti-inflammatory drugs and myocardial infarctions: comparative systematic review of evidence from observational studies and randomised controlled trials
2007
The effects of rituximab on immunocompetency in patients with autoimmune disease
2007
Rheumatoid arthritis
2010 Standout
Tolerance and efficacy of rituximab and changes in serum B cell biomarkers in patients with systemic complications of primary Sjögren's syndrome
2006
Functional Specialization of Interleukin-17 Family Members
2011 Standout
Efficacy and safety of rituximab in moderately‐to‐severely active systemic lupus erythematosus: The randomized, double‐blind, phase ii/iii systemic lupus erythematosus evaluation of rituximab trial
2009
High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal
2005 Standout
The Inflammasomes
2010 Standout
Mechanisms and Functions of Inflammasomes
2014 Standout
A network meta-analysis of randomized controlled trials of biologics for rheumatoid arthritis: a Cochrane overview
2009
Cell death and endoplasmic reticulum stress: disease relevance and therapeutic opportunities
2008 Standout
Rituximab
2007
Emerging cell and cytokine targets in rheumatoid arthritis
2013
Assessment of rituximab's immunomodulatory synovial effects (ARISE trial). 1: clinical and synovial biomarker results
2007
The future of the IL-1 receptor antagonist anakinra: from rheumatoid arthritis to adult-onset Still's disease and systemic-onset juvenile idiopathic arthritis
2008
Rituximab versus Cyclophosphamide in ANCA-Associated Renal Vasculitis
2010 Standout
Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases
2012
Clinical targeting of the TNF and TNFR superfamilies
2013
Rituximab for treatment-resistant extensive Wegener`s granulomatosis—additive effects of a maintenance treatment with leflunomide
2007
Recurrent miscarriage
2006 Standout
Safety of extended treatment with anakinra in patients with rheumatoid arthritis
2006
Can we improve the performance and reporting of investigator-initiated clinical trials? Rheumatoid arthritis as an example
2014
Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis: An open‐label extension analysis
2007
Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial
2008
Treatment of Graves' disease with rituximab specifically reduces the production of thyroid stimulating autoantibodies
2008
Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial
2011
Protein therapeutics: a summary and pharmacological classification
2007 Standout
The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupus-like disease from nephritis
2008
Rapid responses to anakinra in patients with refractory adult‐onset Still's disease
2005
Synthesis of Heterobifunctional Protein Fusions Using Copper‐Free Click Chemistry and the Aldehyde Tag
2012 StandoutNobel
Development of psoriasis after B cell depletion with rituximab
2007
Tumor Necrosis Factor Inhibits Spread of Hepatitis C Virus Among Liver Cells, Independent From Interferons
2017 StandoutNobel
Clinical, radiographic and immunogenic effects after 1 year of tocilizumab-based treatment strategies in rheumatoid arthritis: the ACT-RAY study
2014
Interleukin-6 inhibition for treatment of rheumatoid arthritis: A review of tocilizumab therapy
2010
Rituximab-Associated Infections
2010
Rituximab, B-Lymphocyte Depletion, and Preservation of Beta-Cell Function
2009
New Drugs for Rheumatoid Arthritis
2004
Development of Virus-Like Particle Technology from Small Highly Symmetric to Large Complex Virus-Like Particle Structures
2013 Standout
IL-1 acts directly on CD4 T cells to enhance their antigen-driven expansion and differentiation
2009
Antidrug antibodies in psoriasis: a systematic review
2013
Loss of the Protein Tyrosine Phosphatase PTPN22 Reduces Mannan-Induced Autoimmune Arthritis in SKG Mice
2016 StandoutNobel
Immunological and Inflammatory Functions of the Interleukin-1 Family
2009 Standout
Preparation of Porous Polysaccharides Templated by Coordination Polymer with Three-Dimensional Nanochannels
2017 StandoutNobel
Site-specific chemical modification of recombinant proteins produced in mammalian cells by using the genetically encoded aldehyde tag
2009 StandoutNobel
Atacicept: targeting B cells in multiple sclerosis
2010
Guest authorship and ghostwriting in publications related to rofecoxib: a case study of industry documents from rofecoxib litigation.
2008
A review of the current use of rituximab in autoimmune diseases
2008
Cyclooxygenases: new forms, new inhibitors, and lessons from the clinic
2004
Type 1 Diabetes: Etiology, Immunology, and Therapeutic Strategies
2011
Rituximab for the treatment of rheumatoid arthritis
2009
CONSORT 2010 Explanation and Elaboration: updated guidelines for reporting parallel group randomised trials
2010 Standout
Differentiation of Effector CD4 T Cell Populations
2010 Standout
Generic quality-of-life assessment in rheumatoid arthritis.
2007
LEF-1 is crucial for neutrophil granulocytopoiesis and its expression is severely reduced in congenital neutropenia
2006 Standout
Works of Joy Schechtman being referenced
Concomitant medication use in a large, international, multicenter, placebo controlled trial of anakinra, a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis.
2004
Safety and tolerability of rituximab in patients with moderate to severe rheumatoid arthritis: Results from the dose-ranging assessment international clinical evaluation of rituximab in rheumatoid arthritis (DANCER) study
2005
Anakinra, a recombinant human interleukin‐1 receptor antagonist (r‐metHuIL‐1ra), in patients with rheumatoid arthritis: A large, international, multicenter, placebo‐controlled trial
2003
The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: Results of a phase IIB randomized, double‐blind, placebo‐controlled, dose‐ranging trial
2006
Denosumab‐mediated increase in hand bone mineral density associated with decreased progression of bone erosion in rheumatoid arthritis patients
2010
Ocrelizumab, a humanized anti‐CD20 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: A phase I/II randomized, blinded, placebo‐controlled, dose‐ranging study
2008
The safety of anakinra in high‐risk patients with active rheumatoid arthritis: Six‐month observations of patients with comorbid conditions
2004
Gastrointestinal Tolerability and Effectiveness of Rofecoxib versus Naproxen in the Treatment of Osteoarthritis
2003
The immunogenicity, safety, and efficacy of etanercept liquid administered once weekly in patients with rheumatoid arthritis.
2007